Poster viewing and lunch

69P - Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients (ID 288)

Lecture Time
12:15 - 12:15
Session Name
Poster viewing and lunch
Room
Exhibition area
Date
Fri, 12.05.2023
Time
12:15 - 13:00
Speakers
  • Muhammad U. Rashid (Lahore, Pakistan)
Authors
  • Muhammad U. Rashid (Lahore, Pakistan)
  • Noor Muhammad (Lahore, Pakistan)
  • Humaira Naeemi (Lahore, Pakistan)
  • Umara Shehzad (Lahore, Pakistan)
  • Ute Hamann (Heidelberg, Germany)

Abstract

Background

Knowledge of population specific BRCA1/2 founder mutations provides a valuable and cost-effective genetic testing strategy. Twenty-three recurrent BRCA1 mutations have been identified previously in 100 Pakistani breast and/or ovarian cancer families. These accounted for 72.5% of all BRCA1 mutations identified.

Methods

In this study, we investigated whether these mutations (identified in >2 unrelated patients) have a common ancestral origin and estimated the ages of these mutations. Haplotype analyses were performed in 188 individuals (100 index patients, 88 relatives) from Pakistani breast/ovarian cancer families, all harboring one of the 23 recurrent BRCA1 mutations, and 90 healthy controls. Six microsatellite markers (D17S800, D17S1801, D17S855, D17S1322, D17S1323, and D17S951) were analyzed. Mutation ages were estimated using DMLE+2.3 software.

Results

An identical haplotype of different length was found in families harboring the same BRCA1 mutation and suggested founder effects for all 23 mutations. Sixteen founder mutations were ethnicity-specific: 15 occurred in families of Punjabi background and one in a family of Pathan background. The remaining seven mutations occurred in families with two ethnic backgrounds. All BRCA1 founder mutations were estimated to have arisen approximately 147 to 159 generations ago. Our findings suggest founder effects for all 23 recurrent BRCA1 mutations.

Conclusions

Our findings suggest founder effects for all 23 recurrent BRCA1 mutations. This knowledge allows the design and development of a cost effective local genetic testing strategy in Pakistan.

Legal entity responsible for the study

The authors.

Funding

Foundation or academic group WITHOUT funding from a pharma, biotech, or other commercial company.

Disclosure

All authors have declared no conflicts of interest.

Collapse